FDA Approves Zydelig for Three Hematologic Cancers

Share this content:
FDA Approves Zydelig for Three Hematologic Cancers
FDA Approves Zydelig for Three Hematologic Cancers

Gilead Sciences has announced that the FDA has approved Zydelig (idelalisib) in combination with rituximab for patients with relapsed chronic lymphocytic leukemia for whom rituximab alone would be considered appropriate therapy, as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma, and for small lymphocytic lymphoma who have received at least two prior systemic therapies.

Zydelig is a first-in-class oral inhibitor of PI3K delta, a protein which plays a role in the activation, proliferation, and viability of B cells.

RELATED: Hematologic Cancers Resource Center

Zydelig will be available in 100mg and 150mg strength tablets.

For more information call (800) 445-3235 or visit Gilead.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs